Erratum: Davis G, Surratt H, Levin F, et al. Antiretroviral medication: An emerging category of prescription drug misuse. Am J Addict. 2013. doi: 10.1111/j.1521-0391.2013.12107.x;Antiretroviral medication: An emerging category of prescription drug misuse

American Journal on Addictions

Volumn 23, Issue 6, 2014, Pages 519-525

  Davis, Glen P ^a   Surratt, Hilary L ^b   Levin, Frances R ^a   Blanco, Carlos ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTIRETROVIRUS AGENT; BUPRENORPHINE; CANNABIS; COCAINE; DIAMORPHINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; KETAMINE; METHADONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OXYCODONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; CENTRAL STIMULANT AGENT; NARCOTIC ANALGESIC AGENT;

DIZZINESS; DRUG EFFECT; DRUG INTERACTION; DRUG MISUSE; DRUG TRAFFIC; GANG; HALLUCINATION; HEALTH SURVEY; HUMAN; INSOMNIA; MANIA; NEUROPSYCHIATRY; PRESCRIPTION DRUG DIVERSION; PSYCHOSIS; REVIEW; SOUTH AFRICA; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; THEFT; UNITED STATES; VIVID DREAM; ADDICTION; HIV INFECTIONS;

ANALGESICS, OPIOID; ANTI-RETROVIRAL AGENTS; CANNABIS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; PRESCRIPTION DRUG DIVERSION; PRESCRIPTION DRUG MISUSE; SUBSTANCE-RELATED DISORDERS;

EID: 84921654686     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12300     Document Type: Erratum

References (45)

1. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the Future National Survey Results on Drug Use, 1975-2010. Volume II: College Students and Adults Ages 19-50. Ann Arbor: Institute for Social Research, the University of Michigan; 2010.
2. Caplan JP, Epstein LA, Quinn DK, et al. Neuropsychiatric effects of prescription drug abuse. Neuropsychol Rev. 2007; 17: 363-380.
3. Surratt HL, Kurtz SP, Cicero TJ, O'Grady C, et al. Antiretroviral medication diversion among HIV-positive substance abusers in South Florida. Am J Public Health. 2013; 103: 1026-1028.
4. Eban K., Dangerous Doses: How Counterfeiters Are Contaminating America's Drug Supply, 1st edn. Orlando: Harcourt; 2005.
5. Campanile C., 2012 Four busted in $150M HIV/AIDS-Medicaid drug scam. New York Post. April 4, 2012.
6. Ballantyne C., HIV drugs turned street drugs in South Africa, 2009; http://www.scientificamerican.com/blog/post.cfm?id=hiv-drugs-turned-street-drugs-in-so-2009-04-07 (Accessed October 24, 2011).
7. Sparks C., Addictive drug threatens the future of South African youth. March 15, 2011; http://www.mediaglobal.org/2011/03/15/addictive-drug-threatens-the-future-of-south-african-youth/ (Accessed October 25, 2011).
8. Sciutto J., 'No turning back': Teens abuse HIV drugs, teens in South Africa smoke anti-retroviral drug efavirenz for cheap high. April 8, 2009; http://abcnews.go.com/Health/MindMoodNews/story?id=7227982&page=1 (Accessed October 25, 2011).
9. Black R., Abusing the anti-HIV/AIDS drug efavirenz could have devastating results for South Africans. April 7, 2009; http://articles.nydailynews.com/2009-04-07/entertainment/17919776-1-efavirenz-anti-retroviral-drugs-south-africans (Accessed October 25, 2011).
10. Fihlani P., " Whoonga" threat to South African HIV patients. BBC News. 2011; http://www.bbc.co.uk/news/world-africa-12389399 (Accessed October 24, 2011).
11. Analysis IPGHANa. South Africa: No ARVs in 'whoonga' say experts. February 10, 2011.
12. Inciardi JA, Surratt HL, Kurtz SP, et al. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007; 8: 171-183.
13. Larkan F, Van Wyk B, Saris J., Of remedies and poisons: Recreational use of antiretroviral drugs in the social imagination of South African careers. Afr Sociol Rev. 2010; 14: 62-73.
14. Administration SAMHS, Drug Abuse Warning Network (DAWN). 2012. Accessed January 28, 2013.
15. U.S. Department of Justice DEA, Office of Diversion Control. National Forensic Laboratory Information System, 2011. Midyear Report. 2011; http://www.deadiversion.usdoj.gov/nflis/index.html (Accessed January 28, 2013).
16. Wynn HE, Brundage RC, Fletcher CV., Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs. 2002; 16: 595-609.
17. Maxwell S, Scheftner WA, Kessler HA, et al. Manic syndrome associated with zidovudine treatment. JAMA. 1988; 259: 3406-3407.
18. Colebunders R, Hilbrands R, De Roo A, et al. Neuropsychiatric reaction induced by abacavir. Am J Med. 2002; 113: 616.
19. Wise ME, Mistry K, Reid S., Drug points: Neuropsychiatric complications of nevirapine treatment. BMJ. 2002; 324: 879.
20. Prime K, French P., Neuropsychiatric reaction induced by clarithromycin in a patient on highly active antiretroviral therapy (HAART). Sex Transm Infect. 2001; 77: 297-298.
21. Treisman GJ, Kaplin AI., Neurologic and psychiatric complications of antiretroviral agents. AIDS. 2002; 16: 1201-1215.
22. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009; 11: 103-109.
23. Gazzard B, Balkin A, Hill A., Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: A systematic review. AIDS Rev. 2010; 12: 67-75.
24. Jena A, Sachdeva RK, Sharma A, et al. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: A 24-week prospective study. J Int Assoc Physicians AIDS Care (CHIC). 2009; 8: 318-322.
25. Boscacci RT, Buclin T, Furrer H, et al. A case of voluntary intoxication with efavirenz and lamivudine. AIDS. 2006; 20: 1352-1354.
26. Lowenhaupt EA, Matson K, Qureishi B, et al. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis. 2007; 45: e128-e130.
27. Lochet P, Peyriere H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003; 4: 62-66.
28. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005; 41: 1648-1653.
29. Manfredi R, Calza L, Chiodo F., Efavirenz versus nevirapine in current clinical practice: A prospective, open-label observational study. J Acquir Immune Defic Syndr. 2004; 35: 492-502.
30. Arendt G, de Nocker D, von Giesen HJ, et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007; 6: 147-154.
31. Bertz RJ, Granneman GR., Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997; 32: 210-258.
32. Wynn GH, Cozza KL, Zapor MJ, et al. Med-psych drug-drug interactions update. Antiretrovirals, part III: Antiretrovirals and drugs of abuse. Psychosomatics. 2005; 46: 79-87.
33. Antoniou T, Tseng AL., Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002; 36: 1598-1613.
34. Ladona MG, Gonzalez ML, Rane A, et al. Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Sci. 2000; 68: 431-443.
35. Gruber VA, McCance-Katz EF., Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep. 2010; 7: 152-160.
36. Administration FD, FDA. Drug development and drug interactions: Table of substrates, inhibitors and inducers. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm (Accessed December 4, 2012).
37. Eap CB, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol. 2001; 21: 229-234.
38. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006; 43 (Suppl 4): S224-S234.
39. Henry JA, Hill IR., Fatal interaction between ritonavir and MDMA. Lancet. 1998; 352: 1751-1752.
40. Kreth K, Kovar K, Schwab M, et al. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol. 2000; 59: 1563-1571.
41. Lettieri JT, Fung HL., Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J Pharmacol Exp Ther. 1979; 208: 7-11.
42. Harrington RD, Woodward JA, Hooton TM, et al. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med. 1999; 159: 2221-2224.
43. Palmisano L, Vella S., A brief history of antiretroviral therapy of HIV infection: Success and challenges. Ann Ist Super Sanita. 2011; 47: 44-48.
44. Shesser R, Jotte R, Olshaker J., The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med. 1991; 9: 336-342.
45. Pollard RB., Can HIV infection be treated successfully with a once-daily regimen ? AIDS Read. 2002; 12: 489-490, 494-498, 500, 508.